Table 1.
Genetic Alterations in Pancreatic Acinar Cell Carcinomas
| Case | Age/sex | p53 accumulation | Dpc4 loss | MSI | Nuclear β-catenin | β-catenin mutation | APC mutation | 11p LOH |
|---|---|---|---|---|---|---|---|---|
| A1 | 15 /F | — | — | MSS | — | Wild-type | Wild-type | − |
| A2 | 21 /F | — | — | MSS | — | Wild-type | 1444X | − |
| A3 | 32 /F | — | — | MSS | — | Wild-type | Wild-type | − |
| A4 | 73 /F | — | — | MSI-L | — | Wild-type | Wild-type | + |
| A5 | 51 /M | — | — | MSI-L | 50% | Wild-type | Wild-type | − |
| A6 | 55 /F | — | — | MSS | — | Wild-type | Wild-type | N/I |
| A7 | 2 /F | — | — | MSS | — | Wild-type | Wild-type | + |
| A8 | 70 /M | — | — | MSS | — | Wild-type | Wild-type | − |
| A9 | 76 /M | — | — | MSS | — | Wild-type | Wild-type | + |
| A10 | 58 /M | — | — | MSS | — | Wild-type | Wild-type | − |
| A11 | 31 /M | — | — | MSS | — | Wild-type | Wild-type | + |
| A12 | 80 /M | — | — | MSS | — | Wild-type | Wild-type | + |
| A13 | 31 /M | — | — | N/N | 20% | T41I | Wild-type | N/N |
| A14 | 61 /M | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| A15 | 63 /M | — | — | N/A | — | N/A | N/A | N/A |
| A16 | 76 /M | — | — | N/N | 60% | Wild-type | 1554–1556FS | N/N |
| A17 | 54 /M | — | — | N/A | — | N/A | N/A | N/A |
| A18 | 60 /M | — | — | N/N | — | Wild-type | 1554–1556FS | N/N |
| A19 | 75 /M | — | — | MSI-H | — | Wild-type | Wild-type | + |
| A20 | 74 /M | — | — | N/A | — | N/A | N/A | N/A |
| A21 | 79 /M | — | — | N/N | — | Wild-type | Wild-type | N/N |
Locations of somatic mutations in β-catenin and APC are shown by codon.
Nuclear β-catenin accumulation was evaluated based on the percentage of strongly staining tumor cell nuclei.
FS, frameshift mutation; LOH, loss of heterozygosity; MSI-H, microsatellite instability-high; MSI-L, microsatellite instability-low; MSS, microsatellite stable; N/A, DNA did not amplify or immunohistochemistry failed; N/I, non-informative for allelic loss; N/N, no corresponding normal tissue for evaluation of allelic loss or MSI assays.